ClinicalTrials.gg
CompletedNCT07600827Updated Aug 25, 2026

Isokinetic Training With Blood Flow Restriction for Patellofemoral Pain Syndrome

An interventional study of Isokinetic Training and Isokinetic Training Combined With Blood Flow Restriction in Patellofemoral Pain Syndrome, sponsored by Nanjing Mingzhou Rehabilitation Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Nanjing Mingzhou Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Patellofemoral Pain Syndrome with a site in China — 1 open to participants now, 3 under way, none of them phase 3. Patellofemoral Pain Syndrome · China.

Started
2026
with 4 others
No phase
9 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Nanjing Mingzhou Rehabilitation Hospital

Among the 11 studies in Patellofemoral Pain Syndrome with a site in China, this one is one of 5 that started in 2026, is one of 9 with no phase, and was the 10th registered.

Patellofemoral Pain Syndrome

297 studies on the registry are indexed under Patellofemoral Pain Syndrome; 73 are open to participants now.

Browse Patellofemoral Pain Syndrome studies →

Open to participants now

1 of the 11 studies in Patellofemoral Pain Syndrome with a site in China is open now. Recruiting first, the newest first:

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Patellofemoral Pain Syndrome studies recruiting now, 3 (7%) set no upper age limit and 40 (91%) stop at 75 or younger; 6 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Patellofemoral Pain Syndrome with a site in China, or all of them as a file.
02

Study summary

This randomized controlled trial aims to investigate the effects of isokinetic training combined with blood flow restriction (BFR) in individuals with patellofemoral pain syndrome (PFPS).

03

Conditions studied

  • Patellofemoral Pain Syndrome
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 to 40 years.
  • Clinical diagnosis of patellofemoral pain syndrome (PFPS).
  • Presence of anterior or retropatellar knee pain for at least 3 months.
  • Pain provoked by at least two activities that increase patellofemoral joint load, including squatting, stair climbing, running, jumping, prolonged sitting, or kneeling.
  • Average knee pain intensity of ≥3 on a 10-point visual analog scale (VAS) during aggravating activities.
  • Ability to participate in exercise training and attend scheduled intervention sessions.
  • Willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of knee surgery or significant trauma to the lower extremity within the previous 12 months.
  • Clinical evidence of other knee disorders, including ligament injury, meniscal injury, patellar instability, osteoarthritis, or tendinopathy.
  • Presence of neurological, cardiovascular, or systemic musculoskeletal disorders that may affect lower limb function or exercise participation.
  • Current participation in other structured lower extremity rehabilitation or strength training programs.
  • to blood flow restriction training, including uncontrolled hypertension, vascular disease, thromboembolic disorders, or clotting abnormalities.
  • Use of pain-relieving injections or surgical interventions for knee pain within the previous 6 months.
  • Pregnancy.
  • Inability to complete the assessment or intervention procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IT+BFR group

    Isokinetic Training Combined With Blood Flow Restriction

    Device: Isokinetic Training Combined With Blood Flow Restriction

  • Active comparator
    IT group

    Isokinetic Training

    Device: Isokinetic Training

  • Active comparator
    ACE group

    Aerobic Cycling Exercise

    Device: Aerobic Cycling Exercise

Interventions

  • DeviceIsokinetic Training

    Participants in this group will receive supervised isokinetic muscle strength training targeting the knee musculature using an isokinetic dynamometer. Each session will last 30 minutes throughout the intervention period.

  • DeviceIsokinetic Training Combined With Blood Flow Restriction

    Participants in this group will receive isokinetic muscle strength training combined with blood flow restriction (BFR). BFR will be applied to the proximal thigh using a pneumatic cuff at an individualized pressure based on limb occlusion pressure. Isokinetic training will target the knee musculature using an isokinetic dynamometer under supervised conditions. Each session will last 30 minutes, with training performed multiple times per week throughout the intervention period.

  • DeviceAerobic Cycling Exercise

    Participants in this group will receive supervised aerobic cycling exercise using a stationary bicycle. Training will be performed at a moderate intensity for 30 minutes per session throughout the intervention period.

06

What researchers measure

Primary outcomes

  1. Anterior Knee Pain Scale (AKPS)

    The AKPS is a validated questionnaire used to assess pain and functional limitations associated with patellofemoral pain syndrome. Scores range from 0 to 100, with higher scores indicating better knee function and fewer symptoms.

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

1 site
  • Nanjing Mingzhou Rehabilitation Hospital
    Nanjing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Aug 2026, 2 months.

Of 153 non-industry interventional studies with no phase under Patellofemoral Pain Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 21. This study's 2 months is below that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
May 25, 2026
Primary completionActual
Aug 15, 2026
CompletionActual
Aug 15, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600827
Lead sponsor
Nanjing Mingzhou Rehabilitation Hospital
Collaborators
Guilin institute of information technology
Responsible party
Jingzhi Zhang (Supervisor Technician, Nanjing Mingzhou Rehabilitation Hospital) — Principal investigator
First posted
May 22, 2026
Start date
May 25, 2026
Primary completion
Aug 15, 2026
Completion
Aug 15, 2026
Last update
Aug 25, 2026

Study contacts

Zhang
principal investigator · Nanjing Mingzhou Rehabilitation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion